NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis $4.32 +0.13 (+3.10%) (As of 10:22 AM ET) Add Compare Share Share Today's Range$4.24▼$4.4350-Day Range$3.65▼$4.5552-Week Range$3.25▼$10.45Volume141,304 shsAverage Volume1.32 million shsMarket Capitalization$365.64 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Anavex Life Sciences alerts: Email Address Anavex Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside854.7% Upside$40.00 Price TargetShort InterestBearish24.74% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$32,919 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.55) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector301st out of 879 stocksBiological Products, Except Diagnostic Industry40th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.74% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 4.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 5 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,919.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.55) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.Click here to get your free copy today. About Anavex Life Sciences Stock (NASDAQ:AVXL)Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Read More AVXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Stock News HeadlinesJune 18, 2024 | insidertrades.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Director Peter D.O. Donhauser Buys 2,835 SharesJune 20, 2024 | globenewswire.comAnavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJuly 8, 2024 | Insiders Exposed (Ad)How did they achieve a perfect track record? If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...May 22, 2024 | finance.yahoo.comSector Update: Health Care Stocks Slightly Higher Late AfternoonMay 22, 2024 | globenewswire.comAnavex Life Sciences Announces Expansion of Leadership TeamMay 21, 2024 | finance.yahoo.comAnavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth PlansMay 14, 2024 | globenewswire.comAnavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQMay 13, 2024 | prnewswire.comShareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreJuly 8, 2024 | Insiders Exposed (Ad)How did they achieve a perfect track record? If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...May 10, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)May 10, 2024 | finance.yahoo.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call TranscriptMay 10, 2024 | prnewswire.comShareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreMay 9, 2024 | markets.businessinsider.comBuy Rating on Anavex Life Sciences Amid Promising Alzheimer’s Drug ProspectsMay 9, 2024 | markets.businessinsider.comAVXL Stock Earnings: Anavex Life Sciences Misses EPS for Q2 2024May 9, 2024 | uk.finance.yahoo.comAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 9, 2024 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 8, 2024 | prnewswire.comBERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS WHO PURCHASED ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL)See More Headlines Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/08/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+854.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.04% Return on Assets-26.85% Debt Debt-to-Equity RatioN/A Current Ratio15.12 Quick Ratio15.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book2.42Miscellaneous Outstanding Shares84,640,000Free Float75,331,000Market Cap$354.64 million OptionableOptionable Beta0.63 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Christopher U. Missling M.B.A. (Age 58)M.S., Ph.D., President, CEO, Secretary & Director Comp: $828.25kMs. Sandra Boenisch CPA (Age 43)CGA, Principal Financial Officer & Treasurer Comp: $194.36kMr. Stephan Toutain M.B.A. (Age 58)M.S., Senior VP of Operations & COO Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerClint TomlinsonVP of CorporateDr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentDr. Edward R Hammond M.D.M.P.H., Ph.D., Chief Medical OfficerDr. Kun Jin Ph.D.Head of BiostatisticsMr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsBioanalytical SystemsNASDAQ:BASIBioCryst PharmaceuticalsNASDAQ:BCRXVir BiotechnologyNASDAQ:VIRSana BiotechnologyNASDAQ:SANA4D Molecular TherapeuticsNASDAQ:FDMTView All CompetitorsInsiders & InstitutionsPeter D.O. DonhauserBought 2,835 shares on 6/14/2024Total: $10,319.40 ($3.64/share)Virtu Financial LLCBought 18,954 shares on 5/20/2024Ownership: 0.048%California State Teachers Retirement SystemSold 3,833 shares on 5/16/2024Ownership: 0.096%PEAK6 Investments LLCBought 17,500 shares on 5/15/2024Ownership: 0.000%Steffen ThomasBought 5,000 shares on 5/15/2024Total: $22,600.00 ($4.52/share)View All Insider TransactionsView All Institutional Transactions AVXL Stock Analysis - Frequently Asked Questions How have AVXL shares performed this year? Anavex Life Sciences' stock was trading at $9.31 at the beginning of 2024. Since then, AVXL stock has decreased by 55.0% and is now trading at $4.19. View the best growth stocks for 2024 here. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX) and Geron (GERN). This page (NASDAQ:AVXL) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
